Systematic Review and Meta-Analysis of Seasonal Malaria Chemoprevention

Author:

Thwing Julie1,Williamson John1,Cavros Irene2,Gutman Julie R.1

Affiliation:

1. Malaria Branch, Center for Global Health, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia;

2. U.S. President’s Malaria Initiative, Malaria Branch, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia

Abstract

ABSTRACT. Seasonal malaria chemoprevention (SMC) for children under 5 years of age for up to four monthly cycles during malaria transmission season was recommended by the WHO in 2012 and has been implemented in 13 countries in the Sahel, reaching more than 30 million children annually. Malaria control programs implementing SMC have asked the WHO to consider expanding the age range or number of monthly cycles. We conducted a systematic review and meta-analysis of SMC among children up to 15 years of age and up to six monthly cycles. Twelve randomized studies were included, with outcomes stratified by age (< 5/≥ 5 years), by three or four versus five or six cycles, and by drug where possible. Drug regimens included sulfadoxine–pyrimethamine + amodiaquine, amodiaquine–artesunate, and sulfadoxine–pyrimethamine + artesunate. Included studies were all conducted in Sahelian countries in which high-grade resistance to sulfadoxine–pyrimethamine was rare and in zones with parasite prevalence ranging from 1% to 79%. Seasonal malaria chemoprevention resulted in substantial reductions in uncomplicated malaria incidence measured during that transmission season (rate ratio: 0.27, 95% CI: 0.25–0.29 among children < 5 years; rate ratio: 0.27, 95% CI: 0.25–0.30 among children ≥ 5 years) and in the prevalence of malaria parasitemia measured within 4–6 weeks from the final SMC cycle (risk ratio: 0.38, 95% CI: 0.34–0.43 among children < 5 years; risk ratio: 0.23, 95% CI: 0.11–0.48 among children ≥ 5 years). In high-transmission zones, SMC resulted in a moderately reduced risk of any anemia (risk ratio: 0.77, 95% CI: 0.72–0.83 among children < 5 years; risk ratio: 0.70, 95% CI: 0.52–0.95 among children ≥ 5 years [one study]). Children < 10 years of age had a moderate reduction in severe malaria (risk ratio: 0.53, 95% CI: 0.37–0.76) but no evidence of a mortality reduction. The evidence suggests that in areas in which sulfadoxine–pyrimethamine and amodiaquine remained efficacious, SMC effectively reduced malaria disease burden among children both < 5 and ≥ 5 years old and that the number of cycles should be commensurate with the length of the transmission season, up to six cycles.

Publisher

American Society of Tropical Medicine and Hygiene

Subject

Virology,Infectious Diseases,Parasitology

Reference48 articles.

1. World Malaria Report 2019,2019

2. Childhood mortality and probable causes of death using verbal autopsy in Niakhar, Senegal, 1989–2000;Etard,2004

3. Changes in the pattern of infant and childhood mortality in upper river division, the Gambia, from 1989 to 1993;Jaffar,1997

4. A systematic review and meta-analysis of the efficacy and safety of intermittent preventive treatment of malaria in children (IPTc);Wilson,2011

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3